SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 19, 2007
Intellect Neurosciences, Inc.
(Exact Name Of Registrant As Specified In Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
333-128226 | 20-2777006 |
| (Commission File Number) | (I.R.S. Employer Identification No.) |
| | |
7 West 18th Street, New York, NY | 10011 |
| (Address of Principal Executive Offices) | (Zip Code) |
(212) 448-9300
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On September 19, 2007, Intellect Neurosciences, Inc. (OTCBB: ILNS) (the “Company”) issued a press release to announce that European Patent No. 1237930 covering chimeric peptide vaccines has been validated in nineteen European countries. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
On September 20, 2007, the “Company” issued a press release to announce that announced today that the Company and CHDI, Inc. (“CHDI”) have entered into an agreement under which CHDI will assess Intellect's OXIGONTM as a potential therapy for Huntington disease. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein in its entirety by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished as part of this Report on Form 8-K:
| Exhibit | | Description |
| | | |
| 99.1 | | Press release dated September 19, 2007. |
| 99.2 | | Press release dated September 20, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | INTELLECT NEUROSCIENCES, INC. |
| | | |
| Date: September 25, 2007 | By: | /s/ Elliot Maza |
| | Name: Elliot Maza |
| | Title: President and CFO |
